Irodalom:
1. Katz MHG, Hwang R, Fleming JB, and Evans DB.: Tumor-Node-Metastasis Staging of Pancreatic
Adenocarcinoma CA Cancer J Clin, Mar 2008; 58: 111 – 125.
2. Berger AC, Garcia M, Hoffman JP.: Postresection CA 19-9 Predicts Overall Survival in Patients With
Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704 J.
Clin. Oncol., Dec 2008; 26 6918-5922.
3. Tanaka T, Ikeda M, Okusaka M et al.: Prognostic Factors in Japanese Patients with Advanced Pancreatic
Cancer Treated with Single-agent Gemcitabine as First-line Therapy Jpn. J. Clin. Oncol., November
2008; 38: 755 – 761.
4. Regine WF, Winter KA, Abrams RA.: Fluorouracil vs Gemcitabine Chemotherapy Before and After
Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized
Controlled Trial JAMA, March 5, 2008; 299: 1019 – 1026.
5. Butturini G, Stocken DD, Wente MN, The Pancreatic Cancer Meta-analysis Group.: Influence of Resection
Margins and Treatment on Survival in Patients With Pancreatic Cancer: Meta-analysis of Randomized
Controlled Trials Arch Surg, Jan 2008; 143: 75 – 83.
6. Herman JM, Swartz MJ, Hsu CC.: Analysis of Fluorouracil-Based Adjuvant Chemotherapy and
Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a
Large, Prospectively Collected Database at the Johns Hopkins Hospital JCO Jul 20 2008:3503-3510.
7. Tsao RE, Almhanna K, Lazaryan A.: Is adjuvant radiation plus chemotherapy for resectable pancreatic
adenocarcinoma associated with improved survival? The Cleveland Clinic experience ASCO Meeting
Abstracts, May 2008; 26: 15528.
8. Corsini MM, Miller RC, Haddock MG.: Adjuvant Radiotherapy and Chemotherapy for Pancreatic
Carcinoma: The Mayo Clinic Experience (1975-2005) JCO Jul 20 2008:3511-3516.
9. Haynes JC, Moghanaki D, Morgans A.: Survival following partial pancreatectomy and radiation for
ampullary adenocarcinoma ASCO Meeting Abstracts, May 2008; 26: 15614.
10. Van Laethem J, Van Cutsem E, Hammel P.: Adjuvant chemotherapy alone versus chemoradiation after
curative resection for pancreatic cancer: feasibility results of a randomised EORTC/FFCD/GERCOR
phase II/III study (40013/22012/0304) ASCO Meeting Abstracts, May 2008; 26: 4514.
11. Picozzi VJ, Abrams RA, Traverso LW: ACOSOG Z05031: Report on a multicenter, phase II trial for
adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon ASCO Meeting
Abstracts, May 2008; 26: 4505.
12. Wolpin BM, Hezel AF, Abrams T.: Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory
Metastatic J. Clin. Oncol., Jan 2009; 27: 193-198.
13. Dhillon N, Aggarwal BB, Newman RA.: Phase II Trial of Curcumin in Patients with Advanced Pancreatic
Cancer Clin. Cancer Res., Jul 2008; 14: 4491-99
14. Kim MK, Lee KH, Jang BI.: S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with
Advanced or Metastatic Pancreatic Cancer Jpn. J. Clin. Oncol., January 2009; 39: 49 – 53.
15. Yanagmoto H, Satoi S, MineT.: A multicenter phase I/II study of gemcitabine and personalized peptide
vaccination combination therapy for metastatic pancreatic cancer patients ASCO Meeting Abstracts,
May 2008; 26: 4633.
16. Cohen S. J., Zalupski M. M., Modiano M. R.: A phase I study of imexon inj plus gemcitabine as first-line
Gastro 2009.qxd 5/9/2009 1:42 PM Page 386
A hasnyálmirigy 387
therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity
ASCO Meeting Abstracts, May 2008; 26: 4619.
17. Dragovich T, Laheru DA, Crowley JJ.: Phase II trial of vatalinib in patients with advanced or metastatic
pancreatic adenocarcinoma who failed gemcitabine therapy ASCO Meeting Abstracts, May 2008; 26: 4615.
18. Burtness BA, Powell ME, Berlin JD.: Phase II ECOG trial of irinotecan/docetaxel with or without
cetuximab in metastatic pancreatic cancer: Updated survival and CA19-9 results ASCO Meeting
Abstracts, May 2008; 26: 4642.
19. Kindler HL, Gangadhar T, Karrison T.: Final analysis of a randomized phase II study of bevacizumab
(B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic
cancer (PC) ASCO Meeting Abstracts, May 2008; 26: 4502.
20. Blaszkowsky LS, Zhu AX, Abrams TA.: A phase II study of gemcitabine (G), bevacizumab (B), and
erlotinib (E) in locally advanced (LAPC) and metastatic adenocarcinoma (MPC) of the pancreas ASCO
Meeting Abstracts, May 2008; 26: 15515.
21. Ko AH, Dito E, Schillinger B.: A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients
with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC) ASCO Meeting Abstracts,
May 2008; 26: 4516.
22. Tschoep KE, Boeck S, Berger F.: Regional hyperthermia (RHT) combined with gemcitabine (GEM) +
cisplatin (CIS) in patients with GEM-refractory advanced pancreatic cancer: Results of the ESHO
phase II trial ASCO Meeting Abstracts, May 2008; 26: 4635.
23. Small W, Jr, Berlin J, Freedman GM et al.: Full-Dose Gemcitabine With Concurrent Radiation Therapy
in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial J. Clin. Oncol., Feb
2008; 26: 942 – 947.
24. Evans DB, Varadhachary GR, Crane CH.: Preoperative Gemcitabine-Based Chemoradiation for
Patients With Resectable adenocarcinoma of the Pancreatic Head J. Clin. Oncol., Jul 2008; 26: 3496-3502.
25. Varadhachary GR, Wolff RA, Crane CH.: Preoperative Gemcitabine and Cisplatin Followed by
Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head J. Clin.
Oncol., Jul 2008; 26:3487-3495.
26. Kim G. P., Haddock M., Foster N. R.: Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and
radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer
ASCO Meeting Abstracts, May 2008; 26: 15553.
27. Loehrer PJ, Powell ME, Cardenes HR.: A randomized phase III study of gemcitabine in combination
with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer:
E4201 ASCO Meeting Abstracts, May 2008; 26: 4506.
28. Cardenes H. R., Chiorean E. G., Perkins S.: Neoadjuvant gemcitabine, erlotinib, and hypofractionated
radiation therapy for potentially resectable pancreatic cancer: A pilot study ASCO Meeting Abstracts,
May 2008; 26: 15578.
29. Chaudhary U. B., Gudena V., Milling D. L.: Preliminary results of a phase II neoadjuvant trial with
gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation
therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic
pancreatic cancer ASCO Meeting Abstracts, May 2008; 26: 15506.
30. Demols A, Mahin C, Maréchal R.: Cetuximab plus chemoradiation combined therapy for locally
advanced inoperable pancreatic adenocarcima: A phase I study ASCO Meeting Abstracts, May 2008; 26: 4629.
31. Munter M, Timke C, Abdollahi A.: Final results of a phase II trial [PARC-Study ISRCTN56652283] for
patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated
radiotherapy (IMRT) with cetuximab and gemcitabine ASCO Meeting Abstracts, May 2008; 26: 4613.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 387
388 Gastro Update 2009
32. Duffy A, Kortmansky J, Schwartz G. K.: A phase I study of erlotinib in combination with gemcitabine
and radiation in locally advanced, non-operable pancreatic adenocarcinoma Ann. Onc., January
2008; 19: 86-91.
33. Kleespies A, Ivan Ischenko I, Eichhorn ME. Et al.: Matuzumab Short-Term Therapy in Experimental
Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine Clinical Cancer
Research 14: 5426-5436, September 1, 2008.
34. Angelova AL, Aprahamian M, Grekova SP.: Improvement of Gemcitabine-Based Therapy of Pancreatic
Carcinoma by Means of Oncolytic Parvovirus H-1PV Clin. Cancer Res., Jan 2009; 15: 511-519.
35. Egberts JH, Cloosters V, Noack A.: Anti-Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor
Growth and Metastasis Cancer Res., Mar 2008; 68: 1443-1450.
36. Lang SA, Schachtschneider P, Moser C. et al.: Dual targeting of Raf and VEGF receptor 2 reduces
growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and
pericytes Mol. Cancer Ther., Nov 2008; 7: 3509-3518
37. Melisi D, Ishiyama S, Sclabas GM et al.: LY2109761, a novel transforming growth factor ß receptor
type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Mol. Cancer Ther., Apr 2008; 7: 829-840.
38. Padovani L, Dahan L, Blesius A.: Anticipating gemcitabine-related severe/lethal toxicities: A feasibility
study ASCO Meeting Abstracts, May 2008; 26: 14652.
